Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edouard Louis

Showing results (241-250 of 290) with videos related to

Pageof 29
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 28, 2019
Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's DiseaseEelco C Brand, Sjoerd G Elias, Itta M Minderhoud, et al.
Gut|October 7, 2017
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA studyWilliam J Sandborn, Scott D Lee, Dino Tarabar, et al.
United European Gastroenterology Journal|October 5, 2024
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspectiveTommaso Lorenzo Parigi, Virginia Solitano, Alessandro Armuzzi, et al.
Gut|January 29, 2011
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapyJean-François Rahier, Pavol Papay, Julia Salleron, et al.
Lancet (London, England)|April 17, 2017
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 studyBrian G Feagan, William J Sandborn, Geert D'Haens, et al.
The Lancet. Gastroenterology & Hepatology|January 14, 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialEdouard Louis, Matthieu Resche-Rigon, David Laharie, et al.
Oncotarget|March 15, 2018
Innovative methodology for the identification of soluble biomarkers in fresh tissuesBrunella Costanza, Andrei Turtoi, Akeila Bellahcène, et al.
Journal of Crohn'S & Colitis|September 13, 2020
Solute carrier family 12 member 2 as a proteomic and histological biomarker of dysplasia and neoplasia in ulcerative colitisAngela-Maria Merli, Sophie Vieujean, Charlotte Massot, et al.
Gut|January 26, 2017
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) studyYoram Bouhnik, Franck Carbonnel, David Laharie, et al.
Alimentary Pharmacology & Therapeutics|April 5, 2021
Determinants of IBD-related disability: a cross-sectional survey from the GETAIDJenny Tannoury, Maria Nachury, Carole Martins, et al.
Pageof 29

Showing results (241-250 of 290) with videos related to

Sort By:
Pageof 29
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 28, 2019
Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's DiseaseEelco C Brand, Sjoerd G Elias, Itta M Minderhoud, et al.
Gut|October 7, 2017
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA studyWilliam J Sandborn, Scott D Lee, Dino Tarabar, et al.
United European Gastroenterology Journal|October 5, 2024
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspectiveTommaso Lorenzo Parigi, Virginia Solitano, Alessandro Armuzzi, et al.
Gut|January 29, 2011
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapyJean-François Rahier, Pavol Papay, Julia Salleron, et al.
Lancet (London, England)|April 17, 2017
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 studyBrian G Feagan, William J Sandborn, Geert D'Haens, et al.
The Lancet. Gastroenterology & Hepatology|January 14, 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialEdouard Louis, Matthieu Resche-Rigon, David Laharie, et al.
Oncotarget|March 15, 2018
Innovative methodology for the identification of soluble biomarkers in fresh tissuesBrunella Costanza, Andrei Turtoi, Akeila Bellahcène, et al.
Journal of Crohn'S & Colitis|September 13, 2020
Solute carrier family 12 member 2 as a proteomic and histological biomarker of dysplasia and neoplasia in ulcerative colitisAngela-Maria Merli, Sophie Vieujean, Charlotte Massot, et al.
Gut|January 26, 2017
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) studyYoram Bouhnik, Franck Carbonnel, David Laharie, et al.
Alimentary Pharmacology & Therapeutics|April 5, 2021
Determinants of IBD-related disability: a cross-sectional survey from the GETAIDJenny Tannoury, Maria Nachury, Carole Martins, et al.
Pageof 29